Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 20.37 · gapped above the open, then crossed back over prior close. High/low 21.30 at 7:30 am ET, 20.32 at 10:00 am ET.
Denali Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
via T. Rowe Price Investment Management, Inc., Capital Research Global Investors, Principal Financial Group Inc +11 more · 10.28% of DNLI, 11.16% of CYTK
via T. Rowe Price Investment Management, Inc., Temasek Holdings (Private) Ltd, Norges Bank +3 more · 10.28% of DNLI, 8.64% of ARXS
via T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Capital Research Global Investors +2 more · 10.28% of DNLI, 17.52% of AUR
via T. Rowe Price Investment Management, Inc., Norges Bank, Pictet Asset Management Holding SA +1 more · 10.28% of DNLI, 11.72% of PTC
via T. Rowe Price Investment Management, Inc., Baker Bros. Advisors LP, Siren, L.L.C. +2 more · 10.28% of DNLI, 10.58% of MPLT
via T. Rowe Price Investment Management, Inc., Baker Bros. Advisors LP, Standard Life Aberdeen plc +1 more · 10.28% of DNLI, 22.40% of IMTX
Managers holding a meaningful stake in DNLI also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
DNLI (Denali Therapeutics Inc.) has 7 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SNY +0.12%, in industrials & materials.
295 institutional managers report a position in Denali Therapeutics Inc. worth $4.0B between them, filed on form 13F for the quarter ending 2026-06-30. 28 of them hold 80% of it, the largest being T. Rowe Price Investment Management, Inc. at 10.28%.
270 more managers in the register
28 managers hold 80% of the $4.0B institutional base. The other 267 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.